Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
過去 90 日內有 6 個訊號。
此公司進入各市場的次序 — 由最舊至最新
甘李藥業與JW製藥達成合作
甘李藥業與JW製藥達成合作
註冊以查看完整訊號動態
Gan & Lee Pharmaceuticals 的國際擴張與競爭對手的比較
Gan & Lee Pharmaceuticals你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Gan & Lee Pharmaceuticals你 | 2 | 1 | -100% | 6 | 49 |
Regulatory Affairs VP
查看招聘Bandar Banang Jaya, Johore, Malaysia · 9個月前
Senior Manager, Regulatory Affairs - EU
查看招聘Germany · 11個月前
principal investigator of Biopharmaceuticals
查看招聘Beijing, China · 上年
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
FDA批准甘李藥業的GZR18進行二期臨床試驗，與禮來公司的Tirzepatide進行頭對頭比較，用於肥胖治療。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Gan & Lee Pharmaceuticals 業務、市場及增長訊號的快速解答。
